General
Preferred name
AMIFOSTINE
Synonyms
Ethyol trihydrate ()
WR2721 ()
Amifostine trihydrate ()
WR 2721 ()
Amifostine (hydrate) ()
AMIFOSTINE ANHYDROUS ()
Ethyol ()
Ethiofos ()
Aminopropylaminoethyl thiophosphate ()
2-(3-Aminopropylamino)ethyl thiophosphate ()
S-(2-(3-Aminopropylamino)ethyl) phosphorothioate ()
S-[2-(3-Aminopropylamino)ethyl] phosphorothioate ()
S-[2-[(3-Aminopropyl)amino]ethyl] dihydrogen phosphorothioate ()
SAPEP ()
WR 2721C ()
Amifostine (trihydrate) ()
WR2721 (trihydrate) ()
WR2721 trihydrate ()
Amifostine hydrate ()
WR-2721 ()
Ethiofos anhydrous ()
Amifostine disulfide ()
NSC-296961 ()
Gammaphos ()
WR-2721 TRIHYDRATE ()
YM-08310 ()
NSC-758236 ()
Amifostine (hydrate ()
P&D ID
PD001085
CAS
112901-68-5
63717-27-1
644-99-5
20537-88-6
Tags
prodrug
natural product
drug
available
Approved by
FDA
First approval
1995
Drug Status
investigational
approved
Drug indication
Protectant (topical)
Mucositis
Radioprotector
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Amifostine is a phosphorylated aminosulfhydryl compound. After dephosphorylation of amifostine by alkaline phosphatase to an active free sulfhydryl (thiol) metabolite, the thiol metabolite binds to and detoxifies cytotoxic platinum-containing metabolites of cisplatin and scavenges free radicals induced by cisplatin and ionizing radiation. The elevated activity of this agent in normal tissues results from both the relative abundance of alkaline phosphatase in normal tissues and the greater vascularity of normal tissues compared to tumor tissues. (BOC Sciences Bioactive Compounds)
DESCRIPTION Radioprotective agent; selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy (LOPAC library)
DESCRIPTION Amifostine hydrate is a radiation-protective agent. (BOC Sciences Bioactive Compounds)
Compound Sets
26
AdooQ Bioactive Compound Library
A14238
BOC Sciences Bioactive Compounds
amifostine-cas-20537-88-6-item-84-333150
amifostine-hydrate-cas-63717-27-1-item-400098
Cayman Chemical Bioactives
14398
ChEMBL Approved Drugs
CHEMBL1006
ChEMBL Drugs
CHEMBL1006
Drug Repurposing Hub
DrugBank
DB01143
DrugBank Approved Drugs
DB01143
DrugCentral
156
DrugCentral Approved Drugs
156
DrugMAP
DM5FL14
DrugMAP Approved Drugs
DM5FL14
DrugMatrix
Enamine BioReference Compounds
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1006
MedChem Express Bioactive Compound Library
HY-B0639
HY-B0639A
NCATS Inxight Approved Drugs
ILA426L95O
NIH Approved Oncology Drugs
147094
NIH Mechanistic Set
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
amifostine
TargetMol Bioactive Compound Library
T6381
The Spectrum Collection
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
214.05
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
7
Ring Count
0
Aromatic Ring Count
0
cLogP
-0.25
TPSA
95.58
Fraction CSP3
1.0
Chiral centers
0.0
Largest ring
0.0
QED
0.34
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Cytoprotectant
Indication
renal toxicity
Target
ALPPL2, ENPP1
HIF/HIF Prolyl-Hydroxylase
MDM-2/p53
MOA
reducing agent
Pathway
Apoptosis
Metabolic Enzyme/Protease
Source data